/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Lixte Biotechnology Holdings Inc Share Price Today: Live Updates & Key Insights

Lixte Biotechnology Holdings Inc share price today is $2.74, up -5.84%. The stock opened at $2.91 against the previous close of $2.91, with an intraday high of $2.91 and low of $2.75.

Lixte Biotechnology Holdings Inc Share Price Chart

style
pb-0

Lixte Biotechnology Holdings Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Lixte Biotechnology Holdings Inc Share Price Performance

$2.74 -0.0584(-5.84%) LIXT at 23 Mar 2026 01:59 PM Biotechnology
Lowest Today 2.75
Highest Today 2.91
Today’s Open 2.91
Prev. Close 2.91
52 Week High 6.26
52 Week Low 0.64
Day’s Range: Low 2.75 High 2.91
52-Week Range: Low 0.64 High 6.26
1 day return -
1 Week return -4.3
1 month return -1.7
3 month return -28.46
6 month return -44.42
1 year return +124.03
3 year return -61.62
5 year return -92.4
10 year return -

Lixte Biotechnology Holdings Inc Institutional Holdings

Scotia Capital Inc 2.97

Renaissance Technologies Corp 1.24

Federation des caisses Desjardins du Quebec 1.07

Vanguard Group Inc 0.86

Geode Capital Management, LLC 0.60

DRW Securities, LLC 0.56

Vanguard Institutional Extnd Mkt Idx Tr 0.46

Fidelity Extended Market Index 0.32

Ethos Financial Group LLC 0.29

State Street Corp 0.20

UBS Group AG 0.19

Two Sigma Investments LLC 0.17

Citadel Advisors Llc 0.16

Atlas Legacy Advisors, LLC 0.16

Axxcess Wealth Management, LLC 0.16

Spartan Extended Market Index Pool F 0.11

NT Ext Equity Mkt Idx Fd - NL 0.10

Fidelity Total Market Index 0.10

Fidelity Series Total Market Index 0.08

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.08

Spartan Total Market Index Pool G 0.05

Fidelity Nasdaq Composite Index 0.01

Northern Trust Extended Eq Market Idx 0.00

NT Ext Equity Mkt Idx Fd - L 0.00

NT US Market Cap Idx Fd - L 0.00

SBI Securities Co Ltd 0.00

State St US Extended Mkt Indx NL Cl C 0.00

Bank of America Corp 0.00

Clear Street Group Inc 0.00

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.00

SSgA U.S. Total Market Index Strategy 0.00

Citigroup Inc 0.00

Advisor Group Holdings, Inc. 0.00

HighTower Advisors, LLC 0.00

Tower Research Capital LLC 0.00

Lixte Biotechnology Holdings Inc Market Status

Lixte Biotechnology Holdings Inc Fundamentals

Market Cap 23.85 M

PB Ratio 10.7364

PE Ratio 0.0

Enterprise Value 22.54 M

Total Assets 1.15 M

Volume 31264

Lixte Biotechnology Holdings Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-5686078 -5.7M, FY22:-6304714 -6.3M, FY21:-6735184 -6.7M, FY20:-3263324 -3.3M, FY19:-2390620 -2.4M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:null 0.0M, Q1/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:null 0.0M

Quarterly Net worth Q3/2025:-2030765 -2.0M, Q2/2025:-775673 -0.8M, Q1/2025:-709555 -0.7M, Q3/2024:-986030 -1.0M, Q2/2024:-1010919 -1.0M

About Lixte Biotechnology Holdings Inc & investment objective

Company Information Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

Organisation Biotechnology

Employees 2

Industry Biotechnology

CEO Mr. Geordan G. Pursglove

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow

Lixte Biotechnology Holdings Inc FAQs

What is the share price of Lixte Biotechnology Holdings Inc today?

The current share price of Lixte Biotechnology Holdings Inc is $2.74.

Can I buy Lixte Biotechnology Holdings Inc shares in India?

Yes, Indian investors can buy Lixte Biotechnology Holdings Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Lixte Biotechnology Holdings Inc shares in India?

You can easily invest in Lixte Biotechnology Holdings Inc shares from India by:

Can I buy fractional shares of Lixte Biotechnology Holdings Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Lixte Biotechnology Holdings Inc?

Lixte Biotechnology Holdings Inc has a market cap of $23.85 M.

In which sector does Lixte Biotechnology Holdings Inc belong?

Lixte Biotechnology Holdings Inc operates in the Biotechnology sector.

What documents are required to invest in Lixte Biotechnology Holdings Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Lixte Biotechnology Holdings Inc?

The PE ratio of Lixte Biotechnology Holdings Inc is N/A and the PB ratio is 10.74.